Medical Device
FDA Approves Roche’s Susvimo for Diabetic Macular Edema: A Breakthrough in Continuous Delivery Eye Treatment
Susvimo, ranibizumab, diabetic macular edema, DME, Roche, FDA approval, continuous delivery, eye implant, vision improvement
Trump’s Tariffs Threaten to Disrupt Healthcare Supply Chain and Increase Costs
Trump tariffs, medical supply chain, healthcare costs, drug shortages, medical devices, pharmaceutical industry, import taxes
J&J’s Spravato Surpasses $1 Billion in Revenue for 2024
J&J, Spravato, revenue, 2024, depression treatment, nasal spray
FDA Introduces New Guidance on AI for Drug Approval Submissions in 2025
FDA, AI, drug approval, guidance, regulatory decision-making, medical devices, artificial intelligence, drug development
Regeneron Expands Ophthalmology Portfolio with Acquisition of UK-Based Biotech Oxular
Regeneron, Oxular, Biotech Acquisition, Ophthalmology, Retinal Disorders, Drug Delivery Technology
Abbott and Dexcom Reach 10-Year Settlement Over Diabetes Sensor Patent Disputes
Abbott, Dexcom, diabetes sensor, patent litigation, settlement, 10-year truce, continuous glucose monitoring (CGM)
Gilead Sciences Appoints Dietmar Berger as Chief Medical Officer to Spearhead R&D Revamp
Gilead Sciences, Dietmar Berger, Chief Medical Officer, R&D Reset, Biotechnology, Pharmaceutical Industry
Embecta Discontinues Insulin Patch Pump Program Amid Restructuring Efforts
Embecta, insulin patch pump, discontinuation, restructuring, layoffs, diabetes technology
Roche Advances Alzheimer’s Disease Diagnosis with Breakthrough Blood Test
Alzheimer’s disease, blood test, Roche, Eli Lilly, FDA breakthrough device designation, pTau217, amyloid pathology, early diagnosis.
Merck & Co. and Mestag Therapeutics Collaborate on $1.9 Billion Fibroblast Therapy Deal for Inflammatory Diseases
Merck & Co., Mestag Therapeutics, Fibroblast therapies, Inflammatory diseases, $1.9 billion deal, RAFT platform, Drug target identification